Height matters: re-thinking blood pressure targets through physics, physiology and evolution
Abstract
Current clinical thinking increasingly endorses lowering blood pressure ( BP) as much as a patient can safely tolerate to prevent major adverse cardiovascular events. The roots of this paradigm date to the Veterans Affairs I trial ( 1967) —the first randomized, placebo-controlled study of antihypertensive therapy [1 ]. Despite enrolling only 143 veterans and employing the limited drug armamentarium of the era, the trial showed striking reductions in events among patients whose diastolic BP ranged from 115 to 129 mmHg [1 ]. The enormous treatment effect reflected the extreme cardiovascular stress of malignant hypertension, and it paved the way for the now-standard goal of keeping office BP below 140/90 mmHg [2 ]. Lowering systolic targets to < 130 mmHg or even < 120 mmHg remains contentious. The residual cardiovascular risk within the 120–140 mmHg range is modest compared with earlier eras, making benefit harder to demonstrate without large cohorts, extended follow-up and rigorous safety monitoring [2 ]. In ACCORD-BP, intensive control ( < 120 mmHg) in type 2 diabetics offered no added benefit over < 140 mmHg and increased treat-ment burden [3 ]. The BPROAD trial in China showed only modest gain: 1 cardiovascular event prevented per 65 treated over 4.2 years, at the cost of 1 case of hyperkalemia per 125 and hypotension per 1250 [4 ]. By contrast, SPRINT found a significant benefit in non-diabetic adults, with 1 event prevented per 57 treated, but also 1 case of acute kidney…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.